Abstract
Purpose
There is no evidence-based systemic therapy for patients with progressive meningiomas for whom surgery or external radiotherapy is no longer an option. In this study, the efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with progressive, treatment-refractory meningiomas were evaluated.
Methods
Retrospective analysis of all meningioma patients treated with [177Lu]Lu-DOTA-TATE from 2000 to 2020 in our centre. Primary outcomes were response according to RANO bidimensional and volumetric criteria and progression-free survival (PFS). Overall survival (OS) and tumour growth rate (TGR) were secondary endpoints. TGR was calculated as the percentage change in surface or volume per month.
Results
Fifteen meningioma patients received [177Lu]Lu-DOTA-TATE (7.5–29.6 GBq). Prior to PRRT, all patients had received external radiotherapy, and 14 patients had undergone surgery. All WHO grades were included WHO 1 (n=3), WHO 2 (n=5), and WHO 3 (n=6). After PRRT, stable disease was observed in six (40%) patients. The median PFS was 7.8 months with a 6-month PFS rate of 60%. The median OS was 13.6 months with a 12-month OS rate of 60%. All patients had progressive disease prior to PRRT, with an average TGR of 4.6% increase in surface and 14.8% increase in volume per month. After PRRT, TGR declined to 3.1% in surface (p=0.016) and 5.0% in volume (p=0.013) per month.
Conclusion
In this cohort of meningioma patients with exhaustion of surgical and radiotherapeutic options and progressive disease, it was shown that PRRT plays a role in controlling tumour growth.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are not publicly available, but are available from the corresponding author on reasonable request.
Code availability
Not applicable.
References
Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021:9. https://doi.org/10.3390/biomedicines9030319.
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21:v1–v100. https://doi.org/10.1093/neuonc/noz150.
Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology. 2021;23:1821–34. https://doi.org/10.1093/neuonc/noab150.
Gousias K, Schramm J, Simon M. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg. 2016;125:551–60. https://doi.org/10.3171/2015.9.JNS15754.
McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg. 2010;112:925–33. https://doi.org/10.3171/2009.9.JNS09617.
Ehresman JS, Garzon-Muvdi T, Rogers D, Lim M, Gallia GL, Weingart J, et al. The relevance of Simpson grade resections in modern neurosurgical treatment of World Health Organization grade I, II, and III meningiomas. World Neurosurg. 2018;109:e588–e93. https://doi.org/10.1016/j.wneu.2017.10.028.
Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review J Neurosurg. 2015;122:4–23. https://doi.org/10.3171/2014.7.JNS131644.
Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology. 2014;16:829–40. https://doi.org/10.1093/neuonc/not330.
Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60. https://doi.org/10.1016/j.annonc.2020.03.304.
Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Leaes CG, et al. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol. 2015;8:13185–92.
Barresi V, Alafaci C, Salpietro F, Tuccari G. Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep. 2008;20:485–92.
Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neuro-Oncol. 2004;66:155–66. https://doi.org/10.1023/b:neon.0000013498.19981.55.
Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39:1409–15. https://doi.org/10.1007/s00259-012-2155-3.
Bashir A, Vestergaard MB, Binderup T, Broholm H, Marner L, Ziebell M, et al. Pharmacokinetic analysis of [(68)Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2. Eur J Nucl Med Mol Imaging. 2020;47:2577–88. https://doi.org/10.1007/s00259-020-04759-1.
Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56:347–53. https://doi.org/10.2967/jnumed.114.149120.
Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis. J Nucl Med. 2021;62:507–13. https://doi.org/10.2967/jnumed.120.249607.
Marincek N, Radojewski P, Dumont RA, Brunner P, Muller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171–6. https://doi.org/10.2967/jnumed.114.147256.
Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1407–16. https://doi.org/10.1007/s00259-009-1115-z.
Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro-Oncology. 2016;18:1538–47. https://doi.org/10.1093/neuonc/now060.
Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med. 2015;56:1748–51. https://doi.org/10.2967/jnumed.115.155853.
Minutoli F, Amato E, Sindoni A, Cardile D, Conti A, Herberg A, et al. Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature. Cancer Biother Radiopharm. 2014;29:193–9. https://doi.org/10.1089/cbr.2013.1599.
Hartrampf PE, Hanscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, et al. Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol. 2020;22:29–32. https://doi.org/10.1016/j.ctro.2020.03.002.
Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. https://doi.org/10.1186/1748-717X-7-99.
Muther M, Roll W, Brokinkel B, Zinnhardt B, Sporns PB, Seifert R, et al. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Nuklearmedizin. 2020;59:348–55. https://doi.org/10.1055/a-1200-0989.
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617–24. https://doi.org/10.1158/1078-0432.CCR-16-2743.
Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the response assessment in neuro-oncology working group. Neuro-Oncology. 2019;21:26–36. https://doi.org/10.1093/neuonc/noy137.
US Department of Health and Human Services, National Institute of health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.03. 2010; Accessed September 2021. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
Bolch WE, Eckerman KF, Sgouros G. Thomas Sr. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009;50:477–84. https://doi.org/10.2967/jnumed.108.056036.
Peters SMB, Meyer Viol SL, van der Werf NR, de Jong N, van Velden FHP, Meeuwis A, et al. Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems. EJNMMI Phys. 2020;7:9. https://doi.org/10.1186/s40658-020-0278-3.
Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88. https://doi.org/10.1186/s13550-017-0339-3.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. https://doi.org/10.1007/s00401-016-1545-1.
Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sepulveda JM, et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC brain tumor group (EORTC-1320-BTG). Neuro-Oncology. 2021. https://doi.org/10.1093/neuonc/noab243.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.
Sierra ML, Agazzi A, Bodei L, Pacifici M, Arico D, De Cicco C, et al. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother Radiopharm. 2009;24:659–65. https://doi.org/10.1089/cbr.2009.0641.
Feijtel D, de Jong M, Nonnekens J. Peptide receptor radionuclide therapy: looking back, looking forward. Curr Top Med Chem. 2020;20:2959–69. https://doi.org/10.2174/1568026620666200226104652.
Gogineni VR, Nalla AK, Gupta R, Dinh DH, Klopfenstein JD, Rao JS. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 2011;313:64–75. https://doi.org/10.1016/j.canlet.2011.08.022.
Biau J, Khalil T, Verrelle P, Lemaire JJ. Fractionated radiotherapy and radiosurgery of intracranial meningiomas. Neurochirurgie. 2018;64:29–36. https://doi.org/10.1016/j.neuchi.2014.10.112.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Central nervous system cancers. Version 2.2021. Accessed April 2022. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
Graillon T, Ferrer L, Siffre J, Sanson M, Peyre M, Peyriere H, et al. Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. Neuro-Oncology. 2021;23:1139–47. https://doi.org/10.1093/neuonc/noab019.
Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro-Oncology. 2016;18:1021–7. https://doi.org/10.1093/neuonc/now001.
Hashiba T, Hashimoto N, Izumoto S, Suzuki T, Kagawa N, Maruno M, et al. Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg. 2009;110:675–84. https://doi.org/10.3171/2008.8.JNS08481.
Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114:1250–6. https://doi.org/10.3171/2010.12.JNS101623.
Author information
Authors and Affiliations
Contributions
Concept and design: NSM, EMB, JECB, JH, and TB
Acquisition, analysis, and/or interpretation of data: all authors
Drafting of the manuscript: NSM
Critical revision of the manuscript for important intellectual content: all authors
Statistical analysis: NSM, JH, and TB.
Corresponding author
Ethics declarations
Ethics approval
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Erasmus Medical Centre.
Consent to participate
Informed consent was obtained from all subjects involved in the study, or the need for written informed consent was waived by the medical ethical committee of the Erasmus MC.
Consent for publication
Informed consent was obtained from all subjects involved in the study, or the need for written informed consent was waived by the medical ethical committee of the Erasmus MC.
Conflict of interest
E.M.B has received consultancy fees from BrainLab A.G. W.W.D.H has received speaker fees from AAA-Novartis and Ipsen, compensation from AAA-Novartis and Ipsen for service on advisory boards, and research support from AAA-Novartis. J.H. has received speaker fees from Ipsen and compensation from AAA-Novartis and Ipsen for service on advisory boards. T.B. has received speaker fees from AAA-Novartis and Ipsen, compensation from AAA-Novartis for service on advisory board, and research support from AAA-Novartis. The other authors have no disclosures.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Oncology - Brain
Eelke M. Bos and Reinoud C. de Leeuw shared second authorship.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Minczeles, N.S., Bos, E.M., de Leeuw, R.C. et al. Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. Eur J Nucl Med Mol Imaging 50, 1195–1204 (2023). https://doi.org/10.1007/s00259-022-06044-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-022-06044-9